Showing results (1141-1150 of 6,669) with videos related to

Sort By:
Pageof 667
Annals of Hematology|November 1, 2021
Frontline-matched sibling donor transplant of aplastic anemia patients using primed versus steady-state bone marrow graftsRiad El Fakih, Feras Alfraih, Saud Alhayli, et al.
Annals of Hematology|June 26, 2019
Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia AAnita Shah, Alexander Solms, Sara Wiegmann, et al.
Annals of Hematology|October 19, 2021
Endothelial dysfunction biomarkers in sickle cell disease: is there a role for ADMA and PAI-1?Suellen Rodrigues Martins, Sílvia Letícia de Oliveira Toledo, Aislander Junio da Silva, et al.
Annals of Hematology|October 20, 2021
Pregnancy outcome in women with transfused beta-thalassemia in FranceEmilie Virot, Isabelle Thuret, Sabine Jardel, et al.
Annals of Hematology|October 20, 2021
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphomaMridula Krishnan, R Gregory Bociek, Michelle Fanale, et al.
Annals of Hematology|March 12, 2022
Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from LebanonPeter Noun, Adlette Inati, Rana Raffoul, et al.
Annals of Hematology|March 8, 2022
Dynamic change in peripheral blood WT1 mRNA levels within three cycles of azacitidine predict treatment response in patients with high-risk myelodysplastic syndromesShinpei Harada, Masahiro Onozawa, Daisuke Hidaka, et al.
Annals of Hematology|April 8, 2022
High-flow nasal cannula oxygen in patients with haematological malignancy: a retrospective observational studySimon Tetlow, Rathai Anandanadesan, Leila Taheri, et al.
Annals of Hematology|April 2, 2022
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysisKrischan Braitsch, Alix Schwarz, Katrin Koch, et al.
Annals of Hematology|October 18, 2019
Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trialTomoaki Fujisaki, Takayuki Ishikawa, Hiroyuki Takamatsu, et al.
Pageof 667